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Summary Thirty-five patients with advanced malignant disease have been treated as outpatients with increas-
ing doses (0.1 -00 mcg) of interleukin 2 (IL2) by once daily self-administered subcutaneous (s.c.) injection, 5
days weekly for 8 weeks followed by a 4 week observation period. Systemic side effects were not experienced
by patients at the 3 lower doses. Three patients required dose reduciton from 100 mcg daily because of
intolerance (fever, rash, lethargy, nausea and vomiting) and one patient was discontinued because ofdyspnoea.
We observed immunological effects at the 100 mcg dose (but not at the lower doses). These consisted of (a) a
modest sustained lymphocytosis, (b) eosinophilia in six (out of nine) patients and (c) a significant rise in
IL2-stimulated peripheral blood lymphocyte activated killer (LAK) cell activity in six (out of nine) patients to
a mean of 2.0 times pretreatment levels (P<0.01). Two (out of nine) patients with renal cell carcinoma treated
with 100 mcg daily had partial responses of duration 4 and 9 months respectively and a further three had
disease stabilisation for at least 3 months. Low dose long-term s.c. IL2 is clinically and immunologically
active, and in comparison to other IL2 regimens it has minor toxicity and is easy to administer. These
characteristics make low dose s.c. IL2 suitable for study in the adjuvant setting.
Recombinant interleukin 2 (IL2) administered either alone or
in combination with autologous, in vitro generated lympho-
cyte activated killer (LAK) cells shows considerable promise
in the treatment of a number of types of advanced cancer
such as malignant melanoma and renal cell carcinoma which
respond poorly to conventional therapy (Rosenberg et al.,
1987; West et al., 1987; Fisher et al., 1988). IL2 therapy
administered by intravenous (i.v.) bolus or infusion has
severe toxicity at high doses and LAK cell infusion is com-
plex and costly. The optimal dosage and scheduling of IL2
has not yet been defined, nor has it been established that the
co-infusion of LAK cells is necessary to maximise the thera-
peutic effects of IL2. IL2 toxicity is dose related (Rosenberg
et al., 1987; West et al., 1987). High dose therapy is only
suitable for fit patients. Regimes employing continuous
infusions of IL2 at 'intermediate' doses and without LAK
cell administration have demonstrable immunological and
clinical activity (Allison et al., 1989; Goldstein et al., 1989;
Oliver et al., 1989), raising the possibility that prolonged
treatment with low dose IL2 may prove to be a clinically
effective and non-toxic alternative to intensive regimes. Long-
term i.v. infusion is cumbersome and although patients
treated with 'intermediate' doses of IL2 have not required
intensive care unit support, the toxicity remains substantial.
These factors limit the duration of treatment.
We report the effects of low dose IL2 treatment of patients
with advanced cancer for prolonged periods which for ease
and simplicity of administration in an outpatient setting was
given by once daily self-administered subcutaneous (s.c.)
injection.
Patients and methods
Patients
Between October 1988 and December 1989, 35 patients with
advanced cancer were entered into a study of outpatient
treatment with s.c. IL2. Patients, who were trained to give
their own injections, were treated once daily from Mondays
to Fridays for 8 weeks, followed by a 4 week observation
period. Five patients were initially treated with 0.1 mcg daily,
six with 1 mcg, eight with 10 mcg and then 16 with 100 mcg
daily. Three patients entered subsequent courses of treatment
at higher doses, one at 10 mcg and two at 100 mcg daily.
Patient characteristics are shown in Table I and their sites of
primary disease are listed in Table II. Five patients in the
100 mcg group and five in the lower dosage groups were
treated during most or all of the study period with non-
steroidal anti-inflammatory drugs for pain and two patients
in the 100 mcg group and one in the lower dosage groups
were treated with steroids. On entry, all patients had a
Karnofsky score of at least 60%, an estimated life expectancy
of greater than 4 months and no serious organ dysfunction
or concomitant disease. Patients gave informed consent and
the study was approved by St George's Hospital Ethics
Committee.
Table I Patient characteristics
0.1-10 mcg 100 mcg
group group
Number treated 19 16a
Age: median 60 62
range 40-82 29-83
Sex (female) 8 6
Mean body surface area (m2) 1.76 1.73
Previous systemic treatmentb 10 2
Number of disease sites: 1 10 5
2 7 9
3 1 1
>3 1 1
Number with liver metastases 7 5
aTwo additional patients in the 0.1-10 mcg group subsequently
received 100 mcg daily. bSystemic treatment discontinued >4 weeks
before entry.
Table II Primary disease site
0.1-JO mcg 100 mcg
Primary site group group
Melanoma 4 2a
Breast 2 2
Lung 4 1
Hepatobiliary 2 0
Colon 4 2
Renal cell 0 9
Cervix I 0
Lymphoma (low grade) 1 0
Unknown 1 0
aTwo additional patients in the 0.1-10 mcg group subsequently
received 100 mcg daily.
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Interleukin 2
IL2 (Bioleukin) (Liang et al., 1985) was supplied by Glaxo
Institute for Molecular Biology as a lyophilised powder with
a specific activity of 1.5-1.7 x 106 units mg-' protein (Gillis
et al., 1978; Gearing & Thorpe, 1988). IL2 was reconstituted
at the beginning of each week with sterile water (and 10%
human serum albumin for the three lower dose levels) with
the daily dose made up to 1 ml. Reconstituted IL2, which
was refrigerated until used, was shown to have stable bioacti-
vity for 4 weeks using an IL2 stimulated lymphoblast DNA
synthesis assay (Malkovsky et al., 1987).
Response assessment and monitoring
Patients were staged not more than 2 weeks prior to entry by
full clinical examination, measurement of full blood count,
serum electrolytes and liver function tests, chest radiograph,
CT scan of abdominal and pelvic disease sites and radio-
graphs of bone lesions when present. Patients were seen
weekly during treatment by a specialist nurse and attended
clinic monthly. Full staging was repeated within 4 weeks of
completion of treatment (and similarly after subsequent
courses of treatment, when given). Response and toxicity was
assessed according to standard UICC/WHO criteria (Miller
et al., 1981).
LAK cell generation and measurement ofcytotoxicity
LAK cell activity was measured using the chromium release
cytotoxicity assay described previously (Malkovsky et al.,
1987). In brief, peripheral blood mononuclear cells (PBMC)
were isolated from heparinized blood by lymphoprep (Nyco-
med) density gradient centrifugation and suspended in tissue
culture medium containing 5% human serum and 500 units
ml-' recombinant IL2 (Glaxo). The cells were cultured for
72 h in a humidified atmosphere of 5% CO2 in air at 37°C
prior to the addition of target cells. The T-24 cells (human
urinary bladder carcinoma) (Malkovsky et al., 1987) which
were used as LAK cell targets were pelleted and labelled with
100fiCi of 5"Cr for 90 min. Four effector to target cell ratios
were set up, each in duplicate. After 4 h of incubation, the
supernatants were collected and the radioactivity measured in
a gamma counter. The percentage killing of target cells was
calculated from 100 x (counts in supernatant - control
c.p.m.)/(counts in supernatant following cell lysis with triton
- control c.p.m.) where control c.p.m. is defined as counts in
supernatant following incubation of target cells in medium
alone. Cytotoxicity was expressed as lytic units/l blood where
one lytic unit = the number of effector cells required to lyse
30% of 104 target cells.
Results
Low dose escalation study
No side effects were encountered in any of the 19 patients
treated with doses of between 0.1 and 10 mcg daily apart
from mild erythema at the injection site which occurred in
nine patients. No responses or significant immunological
activity was observed at these doses.
Results at 100 mcg daily
Response Eleven (out of 18) patients completed one 8 week
course of treatment with 100 mcg IL2 daily. Three additional
patients completed 8 weeks treatment with dose reductions
(to 50, 10 and 10 mcg daily) because of side effects (see
below). Four patients (one of whom was also treated with
steroids) failed to complete 8 weeks treatment, three because
of disease progression and one because of side effects. Fur-
ther courses of IL2 therapy were given to five patients; three
received a total of two courses and two received three
courses.
All 18 patients treated with 100 mcg daily (including both
patients previously treated with 10 mcg daily), nine of whom
had renal cell carcinoma, four of whom had melanoma and
two with colorectal cancer, had assessable disease. Two
patients with renal cell carcinoma, treated with 100 mcg daily
IL2 throughout, had partial responses. One responding
patient, who received three courses of IL2, had regression of
unresectable locally recurrent disease with a response dura-
tion of 9 months. The other patient had regression of lymph
node metastases for 4 months. The times to response were 5
and 2 months respectively. Four patients with renal cell
carcnoma, who completed one, two, two and three courses of
IL2, respectively, had stable disease for at least 3 months and
a further two patients with melanoma also had disease stabili-
sation. The remaining patients had disease progression during
therapy with the exception of the patient who was withdrawn
because of side effects.
Side effects at 100 mcg daily
Subcutaneous IL2 treatment was well tolerated by the major-
ity of patients. Mild erythema and occasionally pruritus
occurred at the injection site in all patients; the reaction
usually developed after approximately 12 h and lasted for up
to 60 h. Systemic side effects which were mostly very mild are
summarised in Table III. Fever, shivers and headache were
relatively common. The onset of symptoms was usually
between 4 and 8 h after injection and in the majority of cases
lasted for less than 3 h. In five patients symptoms occurred
predominantly on Mondays. Fevers and shivers were control-
lable with paracetamol in 7 of the 11 cases. Three of the
patients with fevers (including one requiring dose reduction)
were treated with concomitant non-steroidal anti-inflamma-
tory drugs.
Four patients were intolerant of the 100 mcg daily dose.
One patient, who had compromised respiratory function due
to a lung tumour prior to treatment, was withdrawn because
of grade 3 dyspnoea after 2+ weeks therapy, although there
was no evidence of pulmonary oedema in this case. His
symptoms subsequently improved with steroid and broncho-
dilator therapy. The remaining three patients whose side
effects included fever (in two), generalised erythema, head-
ache, lethargy and nausea and vomiting had dose reductions.
Side effects resolved in one patient at 50 mcg daily; the
remaining two required a further dose reduction to 10 mcg
daily.
With the possible exception of the patient described above,
oedema, clinically apparent hypotension and other symptoms
attributable to the capillary leak syndrome (Rosenstein et al.,
1986) did not occur.
No changes in electrolyte levels or serum urea and creatin-
ine were recorded during treatment. Reversible rises in alka-
line phosphatase and hepatic transaminase levels to up to
3 x baseline levels occurred in four patients during the first 2
weeks of treatment.
Table III Systemic toxicity (100 mcg group)
Severity
WHO WHO WHO
Side effect Number grade I grade 2 grade 3
Fever 11 7 4 0
Shivers 3 3 0 0
Headache 4 3 1 0
State of consciousness 5 4 1 0
Nausea + vomiting 4 2 2 0
Dyspepsia 2 2 0 0
Diarrhoea 1 0 1 0
Cutaneous 1 0 1 0
Dyspnoea 1 0 0 b
Total no. affected 14 9 6 1
aToxicity data was available for all 18 patients; patients with WHO
grade 0 toxicity are not included in the table. No patient experienced
grade 4 toxicity. bPatient had moderate dyspnoea due to lung tumour
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Haematological and immunological effects ofIL2
Haematological and immunological data were obtained from
nine patients in the 100 mcg group during their first course of
IL2 treatment.
Total leucocyte count and neutrophil count did not change
during treatment. Falls in Hb which occurred in some
patients during treatment were in all cases attributed to
underlying disease. Suppression of the lymphocyte to below
baseline values during IL2 treatment was only observed dur-
ing the first week (Figure 1); the mean (95% confidence
interval of mean ) on-treatment value for individual patients
was 0.34 (0.03-0.65) x 109 1[' lower than the corresponding
pretreatment value (P<0.05, t-test for paired samples). Dur-
ing the second treatment week a modest lymphocytosis
developed, with a mean elevation of the lymphocyte count of
0.64 (0.12-1.16) x 109 I-1 with respect to the pretreatment
level (P<0.05). This persisted for the remaining 6 treatment
weeks, the mean elevation ranging from 0.72 to 1.0 x 109 1-l,
which in no case was significantly greater than the lympho-
cytosis during week 2. Although suppression of the lympho-
cyte count did not occur during the second and subsequent
weeks, the count for individual patients on day 5 of weeks
2-8 was lower than the corresponding value on day 1 of the
week by a mean of 0.57 (0.15-0.99) x 1091-' during this
period (P<0.05); the fall was particularly marked during
week 3 (Figure 1). Marked eosinophila (1-5.5 x 1091')
developed during treatment in six patients.
IL2-stimulated peripheral blood LAK cell activity before
and during IL2 treatment for nine patients is shown in Table
IV. In six patients, the mean on-treatment LAK cell activity
was significantly greater than the pre-treatment value (t-test).
In these six patients, LAK cell activity rose to its maximum
level between 2 and 3 weeks from the start of treatment. The
overall mean LAK cell activity during IL2 treatment was 2.0
'- 3.5
a) 4
x
4, 2.5
co
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Figure 1 Mean total lymphocyte count during the first 4 weeks
of IL2 therapy, and 4 weeks after discontinuation. Error bars
show the s.e.m. *= 100 mcg daily; * = 10 mcg daily.
fold greater than the pretreatment mean. Although LAK
activity is expressed as lytic units/l blood, the rise in values
during treatment was not simply the consequence of the
lymphocytosis since the rise is also apparent when lytic units
are normalised to effector cell numbers (data not shown).
LAK cell activity was measured in three patients 4 weeks
after discontinuation of IL2 therapy. In none of these
patients did the LAK activity return to pretreatment levels,
although in two out of three, it dropped significantly below
the on-treatment mean. Insufficient data are available to
enable a comparison to be made between the effects of the
first and subsequent courses of IL2, but for the three patients
in whom measurements were made, the level of LAK activity during the second course appears to be at least as high as
that during the first course.
Discussion
We have demonstrated that low-dose subcutaneous IL2 has
clinical and immunological activity associated with only minor toxicity in patients with advanced cancer. At the doses
of IL2 that we have used, prolonged outpatient treatment is
possible with little inconvenience to the patient.
Assays of IL2 activity show significant variation between
laboratories and an international standard for IL2 has only recently been established (Gearing & Thorpe, 1988). Precise
comparisons of the activity of Bioleukin with that of IL2
from different sources, and consequently comparisons be-
tween dosing schedules is therefore difficult. The activity of
the 100 mcg daily dose of IL2 that we have used is approxi- mately 160,000 units. From available information this is the
lowest dose of IL2 that has been reported to have clinical
activity in the treatment of cancer.
We have found IL2 to be well tolerated by the majority of
patients at the 100 mcg daily dose. Although side effects were
not experienced by patients treated with the lower doses, we
did not observe clinical or immunological activity at these
doses either. It may not be possible to find a clinically effective IL2 dose which is completely free from toxicity. The
severity of side effects experienced by our patients was how-
ever substantially less than that reported in studies with
higher ('intermediate') doses of IL2 given by the i.v. route
and by the i.m. route (Sondel et al., 1988; Allison et al., 1989; Oliver et al., 1989; Urba et al., 1990). The relative toxicities
and clinical and immunological effects of equivalent doses of
IL2 given by continuous i.v. infusion and s.c. injection need
to be compared in a controlled study.
The immunological effects that we have recorded with
100 mcg IL2 daily are similar to, but relatively modest in
comparison to those previously reported for i.v. infusion
(Sondel et al., 1988), which probably reflects the differences
in dosing. The minor suppression of lymphocyte count dur-
ing treatment and the development of a sustained lympho- cytosis which we observed rather than the usual pattern of
Table IV Effects of treatment with 100 mcg IL2 daily on LAK cell activity
LAK cell activity ( x 103 Lytic Units I ')
On-treatmenta
95% Confidence P Patient Pre-treatment Mean interval ofmean Post-treatment (On-Pre)'
WW 10.4 17.5 13.7-21.3 14.7 <0.1
EH 12.0 17.1 -57.8-92.0 - NS PW 10.5 23.4 16.7-30.1 - <0.01
TC 4.6 11.4 9.6-13.2 7.4 <0.001
DP 11.8 32.0 2.0-62.0 - NS MB 13.6 33.1 13.6-52.6 = 0.05
DB 4.2 5.3 -3.7-14.3 - NS FF 10.9 20.1 15.4-24.8 14.1 <0.01 AR 7.2 15.8 10.8-20.8 - <0.01
'LAK cell activity was measured at weekly intervals during treatment where possible.
Allpatientsreceived 8weeks IL2except EH (3weeks). 'Thedifference between theon-and pre-treatment values is significant for the group as a whole (Wilcoxon matched-pairs,
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marked on-treatment suppression to below baseline followed
by rebound (Sondel et al., 1988) is also likely to be related to
IL2 dosing (Creekmore et al., 1989). IL2 has recently been
shown to be immunologically active when given by the s.c.
(Atzpodien et al., 1990) and i.m. (Urba et al., 1990) routes.
No clear correlation has been established between the
extent of the haemotological and immunological changes
induced by IL2 and clinical response (Boldt et al., 1988).
However, there are no reports in humans that suggest that
IL2 has clinical activity at doses at which no immunological
effect can be detected. We have shown that 100 mcg of s.c.
IL2 daily is clinically active (in renal cell carcinoma). The
number of patients we have treated is too small to allow
reliable comparisons to be made between our response data
and those reported elsewhere. However our results are similar
to the previously reported response rates of 16-33% in renal
cell carcinoma treated with more toxic IL2 regimens and with
LAK cell infusion (Rosenberg et al., 1987; Fisher et al., 1988;
Marumo et al., 1989). Our results therefore support the
hypothesis that prolonged low dose therapy may be as effica-
cious clinically as short courses of high dose therapy.
We are not able to exclude clinical activity of doses of
10 mcg daily or less because of the relatively small number of
patients treated and because a lower proportion of patients
treated at these doses had tumours of types which are likely
to respond to IL2. Nevertheless our data do not suggest that
IL2 at these doses is likely to be clinically useful as a single
agent.
The simplicity of low dose self-administered s.c. IL2 makes
it very attractive in comparison to other methods of IL2
treatment. IL2 treatment may prove to be more effective in
early than in advanced disease and this form of therapy
would be ideally suited for study as a possible adjuvant in
the treatment of appropriate solid and haematological malig-
nancies, where self-administered outpatient therapy over long
periods would be mandatory. Further studies of low dose s.c.
IL2 and formal comparison with infusional regimes involving
LAK cell adminstration are now required.
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